Palleon Pharmaceuticals
Palleon Pharmaceuticals develops glycoimmune checkpoint inhibitors through glycan editing to target cancer and autoimmune diseases. This biotechnology platform aims to enhance therapeutic efficacy by modulating immune responses to improve patient outcomes.
- Biotechnology
Funding
Raised to date
$147.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Cancer and autoimmune diseases present significant therapeutic challenges due to their complex interactions with the immune system. Current treatments often lack specificity, leading to off-target effects and limited efficacy in modulating immune responses.
Solution
Palleon Pharmaceuticals is developing a novel class of glycoimmune checkpoint inhibitors using glycan editing technology. This approach aims to enhance therapeutic efficacy by precisely modulating immune responses within the tumor microenvironment and in autoimmune disorders. By targeting specific glycans, Palleon's platform seeks to improve the specificity and effectiveness of immunotherapies, potentially leading to better patient outcomes. The glycan editing technology allows for a more targeted approach to modulating the immune system, reducing the risk of systemic side effects.
Target Audience
Palleon's primary target audience includes patients suffering from cancer and autoimmune diseases, as well as pharmaceutical companies seeking innovative immunotherapeutic approaches.
Features
- Glycan editing technology for precise modulation of immune responses
- Development of glycoimmune checkpoint inhibitors
- Targeted approach to enhance therapeutic efficacy in cancer and autoimmune diseases